174 related articles for article (PubMed ID: 34474469)
1. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma.
Ferrari N; Ward G; Gewinner C; Davis MP; Jueliger S; Saini H; Munck J; Smyth T; Ferraldeschi R; Keer H; Lyons J; Sims MJ
Blood Adv; 2021 Oct; 5(20):4003-4016. PubMed ID: 34474469
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.
Ward GA; Zhang Z; Jueliger S; Potapov IS; Davis MP; Boxall AR; Taylor J; Keer H; Biondo A; Lyons JF; Sims M; Smyth T
Cancer Res Commun; 2024 Jun; 4(6):1441-1453. PubMed ID: 38727208
[TBL] [Abstract][Full Text] [Related]
3. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
Crawford N; Stott KJ; Sessler T; McCann C; McDaid W; Lees A; Latimer C; Fox JP; Munck JM; Smyth T; Shah A; Martins V; Lawler M; Dunne PD; Kerr EM; McDade SS; Coyle VM; Longley DB
Mol Cancer Ther; 2021 Sep; 20(9):1627-1639. PubMed ID: 34389694
[TBL] [Abstract][Full Text] [Related]
4. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
Ye W; Gunti S; Allen CT; Hong Y; Clavijo PE; Van Waes C; Schmitt NC
Oncoimmunology; 2020; 9(1):1710398. PubMed ID: 32002309
[TBL] [Abstract][Full Text] [Related]
5. Novel smac mimetic ASTX660 (Tolinapant) and TNF-α synergistically induce necroptosis in bladder cancer cells in vitro upon apoptosis inhibition.
Wang L; Hu C; Zhao Y; Hu X
Biochem Biophys Res Commun; 2022 Apr; 602():8-14. PubMed ID: 35247703
[TBL] [Abstract][Full Text] [Related]
6. A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma.
Mita MM; LoRusso PM; Papadopoulos KP; Gordon MS; Mita AC; Ferraldeschi R; Keer H; Oganesian A; Su XY; Jueliger S; Tolcher AW
Clin Cancer Res; 2020 Jun; 26(12):2819-2826. PubMed ID: 31900279
[TBL] [Abstract][Full Text] [Related]
7. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
[TBL] [Abstract][Full Text] [Related]
8. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
[TBL] [Abstract][Full Text] [Related]
9. A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).
Johnson CN; Ahn JS; Buck IM; Chiarparin E; Day JEH; Hopkins A; Howard S; Lewis EJ; Martins V; Millemaggi A; Munck JM; Page LW; Peakman T; Reader M; Rich SJ; Saxty G; Smyth T; Thompson NT; Ward GA; Williams PA; Wilsher NE; Chessari G
J Med Chem; 2018 Aug; 61(16):7314-7329. PubMed ID: 30091600
[TBL] [Abstract][Full Text] [Related]
10. New targets of therapy in T-cell lymphomas.
Erter J; Alinari L; Darabi K; Gurcan M; Garzon R; Marcucci G; Bechtel MA; Wong H; Porcu P
Curr Drug Targets; 2010 Apr; 11(4):482-93. PubMed ID: 20196721
[TBL] [Abstract][Full Text] [Related]
11. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
[TBL] [Abstract][Full Text] [Related]
12. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
Ravi D; Bhalla S; Gartenhaus RB; Crombie J; Kandela I; Sharma J; Mazar A; Evens AM
Clin Cancer Res; 2014 Dec; 20(23):6023-33. PubMed ID: 25316819
[TBL] [Abstract][Full Text] [Related]
13. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.
Gibson JF; Alpdogan O; Subtil A; Girardi M; Wilson LD; Roberts K; Foss F
J Am Acad Dermatol; 2015 Jun; 72(6):1010-5.e5. PubMed ID: 25981001
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic Shifts in Primary Cutaneous γδ T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens.
Agbay RL; Torres-Cabala CA; Patel KP; Merril ED; Duvic M; Quesada A; Prieto VG; Aung PP; Loghavi S; Young KH; Hu S; Ferrufino-Schmidt MC; Tetzlaff M; Li S; Medeiros LJ; Miranda RN
Am J Surg Pathol; 2017 Apr; 41(4):431-445. PubMed ID: 28248813
[TBL] [Abstract][Full Text] [Related]
16. Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.
Xiao R; Allen CT; Tran L; Patel P; Park SJ; Chen Z; Van Waes C; Schmitt NC
Oncoimmunology; 2018; 7(9):e1471440. PubMed ID: 30393585
[TBL] [Abstract][Full Text] [Related]
17. Regulation of innate and adaptive antitumor immunity by IAP antagonists.
Dougan SK; Dougan M
Immunotherapy; 2018 Jul; 10(9):787-796. PubMed ID: 29807457
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
[TBL] [Abstract][Full Text] [Related]
19. Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Mehta-Shah N; Lunning MA; Moskowitz AJ; Boruchov AM; Ruan J; Lynch P; Hamlin PA; Leonard J; Matasar MJ; Myskowski PL; Marzouk E; Nair S; Sholklapper T; Minnal V; Palomba ML; Vredenburgh J; Kumar A; Noy A; Straus DJ; Zelenetz AD; Schoder H; Rademaker J; Schaffer W; Galasso N; Ganesan N; Horwitz SM
Am J Hematol; 2021 Oct; 96(10):1211-1222. PubMed ID: 34251048
[TBL] [Abstract][Full Text] [Related]
20. Canine CD4+ T-cell lymphoma identified by flow cytometry exhibits a consistent histomorphology and gene expression profile.
Harris LJ; Hughes KL; Ehrhart EJ; Labadie JD; Yoshimoto J; Avery AC
Vet Comp Oncol; 2019 Sep; 17(3):253-264. PubMed ID: 30684308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
